NVDA
NVIDIA
-- 130.390 TSLA
Tesla
-- 479.860 QUBT
Quantum Computing
-- 16.790 AVGO
Broadcom
-- 240.230 PLTR
Palantir
-- 74.390 
$Galecto (GLTO.US)$ NEWS Galecto Announces First Patient Dos...
NEWS
Galecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab
Galecto, Inc. announced the enrollment of the first patient in an investigator-initiated Phase 2 trial to evaluate GB1211, a galectin-3 inhibitor, in combination with pembrolizumab for metastatic melanoma and head and neck squamous cell carcinoma. Galecto aims to explore GB1211's potential to enhance the effectiveness of pembrolizumab in various cancer indications.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment